Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality
rate. Although the current standard therapy consists of surgery followed by radiation and …

Highlights•Temozolomide resistance can be induced by glioblastoma cells.•Resistance to
temozolomide is caused by multiple mechanisms.•Different resistance pathways exist in …

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Glioblastoma (GBM) is the most malignant primary brain tumor. The current standard
approach in GBM is surgery, followed by treatment with radiation and temozolomide (TMZ); …

Glioblastoma multiforme (GBM) is the most common primary brain tumour, and the most
aggressive in nature. The prognosis for patients with GBM remains poor, with a median …

Background Glioblastoma (GBM) is almost invariably fatal due to failure of standard therapy.
The relapse of GBM following surgery, radiation, and systemic temozolomide (TMZ) is …

Overcoming the resistance of glioblastoma cells against temozolomide, the first-line
chemotherapeutic agent of choice for newly diagnosed glioblastoma, is a major therapeutic …

Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment of
brain tumors remains a challenge. This is particularly true for the most frequent and fatal …

Background The use of temozolomide (TMZ) has improved the prognosis for glioblastoma
multiforme patients. However, TMZ resistance may be one of the main reasons why …

Glioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central
nervous system and the most malignant tumor among gliomas. Despite aggressive …